Similarly, DACT-2 promoter methylation was more frequent in serum collected from PCa patients compared to those with benign disease or controls (qMSP; PCa patients n = 64; BPH patients n = 22; HDs n = 47) [49], showing strong correlations with the Gleason score and nodal involvement, and outperforming PSA levels in specificity (75% vs. 59%). The gene discussed is KLK3; the disease is benign prostatic hyperplasia.